These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22065080)

  • 1. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
    Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
    Müller A; Gillissen B; Richter A; Richter A; Chumduri C; Daniel PT; Scholz CW
    Cell Death Dis; 2018 Mar; 9(3):384. PubMed ID: 29515122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
    Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
    Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
    Brachmann SM; Kleylein-Sohn J; Gaulis S; Kauffmann A; Blommers MJ; Kazic-Legueux M; Laborde L; Hattenberger M; Stauffer F; Vaxelaire J; Romanet V; Henry C; Murakami M; Guthy DA; Sterker D; Bergling S; Wilson C; Brümmendorf T; Fritsch C; Garcia-Echeverria C; Sellers WR; Hofmann F; Maira SM
    Mol Cancer Ther; 2012 Aug; 11(8):1747-57. PubMed ID: 22653967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
    J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
    Jane EP; Premkumar DR; Morales A; Foster KA; Pollack IF
    J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
    Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
    Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.